LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling

Hypertension

Volumn 55, Issue 2, 2010, Pages 257-263

  Bian, Zhou Yan ^a,b   Huang, He ^a,b   Jiang, Hong ^a,b   Shen, Di Fei ^a,b   Yan, Ling ^a,b   Zhu, Li Hua ^a,b   Wang, Lang ^a,b   Cao, Feng ^a,b   Liu, Chen ^c   Tang, Qi Zhu ^a,b   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Calcineurin; Cardiac hypertrophy; Fibrosis; Lmcd1; NFAT

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; LIM AND CYSTEINE RICH DOMAINS 1; LIM PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; ECHOCARDIOGRAPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CALCINEURIN; CARDIOMEGALY; CELLS, CULTURED; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; RANDOM ALLOCATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 74949112895     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135665     Document Type: Article

References (27)

1. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intra-cellular signaling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
2. Dorn GW II. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 2009;6:283-291.
3. Molkentin JD, Robbins J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol. 2009;46:130-136.
4. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49:962-970.
5. Cai J, Yi FF, Yang L, Shen DF, Yang Q, Li A, Ghosh AK, Bian ZY, Yan L, Tang QZ, Li H, Yang XC. Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension. 2009;53:539-548.
6. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hyper-trophic response in coordination with the MAPKs. Cardiovasc Res. 2004; 63:467-475.
7. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004;5:920-931.
8. Schmeichel KL, Beckerle MC. The LIM domain is a modular protein-binding interface. Cell. 1994;79:211-219.
9. Schmeichel KL, Beckerle MC. Molecular dissection of a LIM domain. Mol Biol Cell. 1997;8:219-230.
10. Bespalova IN, Burmeister M. Identification of a novel LIM domain gene, LMCD1, and chromosomal localization in human and mouse. Genomics. 2000;63:69-74.
11. Rath N, Wang Z, Lu MM, Morrisey EE. LMCD1/Dyxin is a novel transcriptional cofactor that restricts GATA6 function by inhibiting DNA binding. Mol Cell Biol. 2005;25:8864-8873.
12. Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang GQ, Ma WZ, Wang W. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med. 2009;87:249-260.
13. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension. 2007;49: 1399-1408.
14. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB, Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang CC. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and-independent signal pathways. Free Radic Biol Med. 2006;40:1756-1775.
15. Li HL, Yin R, Chen D, Liu D, Wang D, Yang Q, Dong YG. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J Cell Biochem. 2007;100:1086-1099.
16. Heineke J, Ruetten H, Willenbockel C, Gross SC, Naguib M, Schaefer A, Kempf T, Hilfiker-Kleiner D, Caroni P, Kraft T, Kaiser RA, Molkentin JD, Drexler H, Wollert KC. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci USA. 2005;102:1655-1660.
17. Jeong D, Kim JM, Cha H, Oh JG, Park J, Yun SH, Ju ES, Jeon ES, Hajjar RJ, Park WJ. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res. 2008;102:711-719.
18. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527-537.
19. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet. 1998;14: 156-162.
20. Luft FC. Dysferlin, dystrophy, and dilatative cardiomyopathy. J Mol Med. 2007;85:1157-1159.
21. Gross V, Obst M, Kiss E, Janke J, Mazak I, Shagdarsuren E, Muller DN, Langenickel TH, Grone HJ, Luft FC. Cardiac hypertrophy and fibrosis in chronic L-NAME-treated AT2 receptor-deficient mice. J Hypertens. 2004;22:997-1005.
22. Lambrechts D, Carmeliet P. Sculpting heart valves with NFATc and VEGF. Cell. 2004;118:532-534.
23. Wu X, Chang B, Blair NS, Sargent M, York AJ, Robbins J, Shull GE, Molkentin JD. Plasma membrane Ca2 +-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J Clin Invest. 2009;119:976-985.
24. Crabtree GR. Pi-by-no signals and specific outcomes: signaling through Ca2 +, calcineurin, and NF-AT. Cell. 1999;96:611-614.
25. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472-484.
26. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. 2000;87:E61-E68.
27. Van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004; 94:E18-E26.